Crizotinib Continuation Clinical Study

StatusActive, Not Recruiting
PhasePhase 4
SponsorPfizer
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

  1. Site details revised at 1 of 13 sitesv24
  2. Enrollment target: 26 to 27v23
  3. Study sites: 15 to 13
    • Primary and study completion dates: Mar 15, 2028 to Mar 21, 2028
    v22
  4. Re-verified, no change to tracked fieldsv21
  5. Primary and study completion dates: Dec 26, 2026 to Mar 15, 2028
    • Trial status: Recruiting to Active, Not Recruiting
    • Enrollment target: estimated 80 to confirmed 26
    • Study sites: 16 to 15
    v20
Show 18 earlier versionsHide 18 earlier versions
  1. Site details revised at 1 of 16 sitesv19
  2. Site details revised at 3 of 16 sitesv18
  3. Study sites: 15 to 16v17
  4. Study sites: 14 to 15v16
  5. Study sites: 12 to 14v15
  6. Study sites: 8 to 12v14
  7. Study sites: 7 to 8v13
  8. Site details revised at 2 of 7 sitesv12
  9. Site details revised at 1 of 7 sitesv11
  10. Study sites: 6 to 7v10
  11. Study sites: 5 to 6v9
  12. Study sites: 4 to 5v8
  13. Study sites: 3 to 4v7
  14. Site details revised at 1 of 3 sitesv6
  15. Study sites: 2 to 3v5
  16. Site details revised at 2 of 2 sitesv4
  17. Study sites: 1 to 2v3
  18. Trial status: Not Yet Recruiting to Recruiting
    • Study sites: 0 to 1
    • Primary and study completion dates: Dec 30, 2026 to Dec 26, 2026
    • Start date changed from estimate of Dec 31, 2021 to Dec 27, 2021
    v2
  1. Study First Submitted
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The purpose of this continuation study is to provide continued access to crizotinib treatment for eligible participants from a current Pfizer sponsored crizotinib clinical study that is planned to close.
Trial Details
NCT Number NCT05160922
Lead Sponsor Pfizer
Conditions
(from sponsor)		 NSCLC, ALCL, IMT
Related terms Carcinoma, Non-Small-Cell Lung, Granuloma, Plasma Cell, Lymphoma, Large-Cell, Anaplastic
Enrollment 27 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov